Back to results
US 2023/0146903 A1Published application
CXCR5 Antagonists and Methods of Treating Diseases or Disorders Using Same
AssigneeYale University
InventorsElias Lolis, Francine Foss, Demetrios Braddock, Yulia Surovtseva, Christopher Fanger, Mark Plummer, Denton Hoyer, Elizabeth Spencer
Life of this patent
Estimating the term…
Abstract
The disclosure provides compounds, and compositions comprising such compounds, that can be used to treat CXCR5-expressing cancers, especially angioimmunoblastic T cell lymphoma (AICL) and/or cutaneous T cell lymphoma (CTCL).
Claims16
A method of treating or ameliorating a CXCR5-expressing cancer in a subject, wherein the method comprises administering to the subject a therapeutically effective amount of a compound selected from:
- 2-(3-methyl-2-(2-methylprop-1-en-1-yl)benzamido)-2,3-dihydro-1H-indene-2-carboxylic acid,
- 2-(2-isobutyl-3-methylbenzamido)-2,3-dihydro-1H-indene-2-carboxylic acid,
- or a salt, solvate, or tautomer thereof, or any mixtures thereof.
Dependencies are inferred from the claim text.